famotidine has been researched along with Body Weight in 4 studies
Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Minimal toxicologic effects (after acute, subacute, or chronic administration) have been observed even at extremely high dosage levels (4,000 mg/kg/day) and for extended periods of administration (2,000 mg/kg/day for 105 weeks)." | 1.27 | Famotidine: summary of preclinical safety assessment. ( Bokelman, DL; Burek, JD; Majka, JA, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (25.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lesclous, P | 1 |
| Guez, D | 1 |
| Baroukh, B | 1 |
| Vignery, A | 1 |
| Saffar, JL | 1 |
| Malcolm, WF | 1 |
| Gantz, M | 1 |
| Martin, RJ | 1 |
| Goldstein, RF | 1 |
| Goldberg, RN | 1 |
| Cotten, CM | 1 |
| Linday, LA | 1 |
| Tsiouris, JA | 1 |
| Cohen, IL | 1 |
| Shindledecker, R | 1 |
| DeCresce, R | 1 |
| Burek, JD | 1 |
| Majka, JA | 1 |
| Bokelman, DL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of Non-nutritive Sucking on Gastroesophageal Reflux, Apneas and Bradycardias in Symptomatic Preterm Infants.[NCT02023216] | 30 participants (Actual) | Observational | 2013-05-31 | Completed | |||
| Generic Database: A Survey of Morbidity and Mortality in Very Low Birth Weight Infants[NCT00063063] | 80,000 participants (Anticipated) | Observational | 1987-01-31 | Recruiting | |||
| Effect of Different Modalities of Enteral Tube Feeding (ETF) on Gastroesophageal Reflux (GER) in Symptomatic Preterm Infants[NCT02837627] | 31 participants (Actual) | Observational | 2016-01-01 | Completed | |||
| Follow-up Visit of High Risk Infants[NCT00009633] | 68,000 participants (Anticipated) | Observational | 1993-01-31 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for famotidine and Body Weight
| Article | Year |
|---|---|
Famotidine treatment of children with autistic spectrum disorders: pilot research using single subject research design.
Topics: Autistic Disorder; Body Weight; Brain; Child; Child, Preschool; Dose-Response Relationship, Drug; Do | 2001 |
3 other studies available for famotidine and Body Weight
| Article | Year |
|---|---|
Histamine participates in the early phase of trabecular bone loss in ovariectomized rats.
Topics: Animals; Body Weight; Bone Resorption; Cimetidine; Famotidine; Female; Femur; Histamine; Immunohisto | 2004 |
Use of medications for gastroesophageal reflux at discharge among extremely low birth weight infants.
Topics: Body Weight; Child Development; Cohort Studies; Continuity of Patient Care; Dose-Response Relationsh | 2008 |
Use of medications for gastroesophageal reflux at discharge among extremely low birth weight infants.
Topics: Body Weight; Child Development; Cohort Studies; Continuity of Patient Care; Dose-Response Relationsh | 2008 |
Use of medications for gastroesophageal reflux at discharge among extremely low birth weight infants.
Topics: Body Weight; Child Development; Cohort Studies; Continuity of Patient Care; Dose-Response Relationsh | 2008 |
Use of medications for gastroesophageal reflux at discharge among extremely low birth weight infants.
Topics: Body Weight; Child Development; Cohort Studies; Continuity of Patient Care; Dose-Response Relationsh | 2008 |
Use of medications for gastroesophageal reflux at discharge among extremely low birth weight infants.
Topics: Body Weight; Child Development; Cohort Studies; Continuity of Patient Care; Dose-Response Relationsh | 2008 |
Use of medications for gastroesophageal reflux at discharge among extremely low birth weight infants.
Topics: Body Weight; Child Development; Cohort Studies; Continuity of Patient Care; Dose-Response Relationsh | 2008 |
Use of medications for gastroesophageal reflux at discharge among extremely low birth weight infants.
Topics: Body Weight; Child Development; Cohort Studies; Continuity of Patient Care; Dose-Response Relationsh | 2008 |
Use of medications for gastroesophageal reflux at discharge among extremely low birth weight infants.
Topics: Body Weight; Child Development; Cohort Studies; Continuity of Patient Care; Dose-Response Relationsh | 2008 |
Use of medications for gastroesophageal reflux at discharge among extremely low birth weight infants.
Topics: Body Weight; Child Development; Cohort Studies; Continuity of Patient Care; Dose-Response Relationsh | 2008 |
Use of medications for gastroesophageal reflux at discharge among extremely low birth weight infants.
Topics: Body Weight; Child Development; Cohort Studies; Continuity of Patient Care; Dose-Response Relationsh | 2008 |
Use of medications for gastroesophageal reflux at discharge among extremely low birth weight infants.
Topics: Body Weight; Child Development; Cohort Studies; Continuity of Patient Care; Dose-Response Relationsh | 2008 |
Use of medications for gastroesophageal reflux at discharge among extremely low birth weight infants.
Topics: Body Weight; Child Development; Cohort Studies; Continuity of Patient Care; Dose-Response Relationsh | 2008 |
Use of medications for gastroesophageal reflux at discharge among extremely low birth weight infants.
Topics: Body Weight; Child Development; Cohort Studies; Continuity of Patient Care; Dose-Response Relationsh | 2008 |
Use of medications for gastroesophageal reflux at discharge among extremely low birth weight infants.
Topics: Body Weight; Child Development; Cohort Studies; Continuity of Patient Care; Dose-Response Relationsh | 2008 |
Use of medications for gastroesophageal reflux at discharge among extremely low birth weight infants.
Topics: Body Weight; Child Development; Cohort Studies; Continuity of Patient Care; Dose-Response Relationsh | 2008 |
Use of medications for gastroesophageal reflux at discharge among extremely low birth weight infants.
Topics: Body Weight; Child Development; Cohort Studies; Continuity of Patient Care; Dose-Response Relationsh | 2008 |
Famotidine: summary of preclinical safety assessment.
Topics: Administration, Oral; Animals; Body Weight; Dogs; Dose-Response Relationship, Drug; Drug Evaluation; | 1985 |